Cambrex Corporation (CBM) and Benitec Biopharma Limited (NASDAQ:BNTC) Comparison side by side

Since Cambrex Corporation (NYSE:CBM) and Benitec Biopharma Limited (NASDAQ:BNTC) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Disclaimer: StocksBeat inform you that the data in this website is not necessarily real-time nor accurate. All prices are not provided by exchanges and prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Stocksbeat doesn`t bear any responsibility for any trading losses you might incur as a result of using the data.